13.95USDMkt Cap: 405.64M USDP/E: —Last update: 2026-05-22
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company's product pipeline comprises EDP-514, which is in phase 1b clinical …
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Company
Market Cap405.64M USD
Enterprise Value425.00M USD
Revenue (TTM)69.21M USD
Gross Profit69.21M USD
Net Income (TTM)-81.89M USD
Revenue/Share2.754 USD
Last Price13.95 USD
Fiscal Year EndSep 2025
MR QuarterMar 2026
Employees120
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS29251M1062
Valuation
P/E (Trailing)—
P/E (Forward)-7.07
PEG—
EV/EBITDA-7.66
EV/Revenue6.14
P/S5.81
P/B3.17
EPS (TTM)-2.60
EPS (Forward)-1.96
52W Range
13.7926% of range14.40
52W High14.40 USD
52W Low13.79 USD
Profitability
Gross Margin100.00%
Oper. Margin-69.07%
EBITDA Margin-80.12%
Profit Margin-125.36%
ROE-126.53%
ROA-29.17%
Growth
Revenue Growth15.00%
Earnings Growth—
Cash Flow & Leverage
Operating CF-19.27M USD
CapEx (TTM)12.90M USD
FCF Margin11.11%
FCF Yield1.90%
Net Debt22.84M USD
Net Debt/EBITDA-0.41
Balance Sheet
Debt/Equity0.89
Current Ratio3.84
Quick Ratio3.69
Book Value/Sh4.362 USD
Cash/Share5.632 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.2 (Strong Buy)
Target (Mean)20.14 USD
Target Range14.00 USD – 28.00 USD
# Analysts7
Ownership
Shares Out.29.08M
Float20.06M
Insiders4.68%
Institutions92.80%
Short Interest
Short Ratio18.2d
Short % Float8.89%
Short % Out.7.43%
Shares Short2.16M
Short (prev mo.)2.13M
Technical
SMA 5013.60 (+2.5%)
SMA 20012.30 (+13.4%)
Beta1.01
S&P 52W Chg28.31%
Avg Vol (30d)136.69K
Avg Vol (10d)227.38K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—